Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Holstein

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|June 1, 2018
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine ScaffoldMichael Forster, Apirat Chaikuad, Teodor Dimitrov, et al.
Experimental Dermatology|October 28, 2020
The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibitionKatharina Pietschke, Julia Holstein, Katharina Meier, et al.
Cell Chemical Biology|November 15, 2016
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding PocketMichael Forster, Apirat Chaikuad, Silke M Bauer, et al.
Inflammation|January 6, 2026
Inhibition of the JAK/STAT Signaling Pathway Suggests a Protective Effect against Acantholysis in PemphigusFarzan Solimani, Julia Holstein, Katharina Meier, et al.
Scientific Reports|March 15, 2017
Nutritional control of IL-23/Th17-mediated autoimmune disease through HO-1/STAT3 activationJürgen Brück, Julia Holstein, Ivana Glocova, et al.
The Journal of Allergy and Clinical Immunology|November 22, 2020
Immunophenotyping in pemphigus reveals a T<sub>H</sub>17/T<sub>FH</sub>17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody productionJulia Holstein, Farzan Solimani, Carolin Baum, et al.
Theranostics|July 9, 2019
Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactionsJohannes Schwenck, Andreas Maurer, Birgit Fehrenbacher, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|June 1, 2018
Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine ScaffoldMichael Forster, Apirat Chaikuad, Teodor Dimitrov, et al.
Experimental Dermatology|October 28, 2020
The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibitionKatharina Pietschke, Julia Holstein, Katharina Meier, et al.
Cell Chemical Biology|November 15, 2016
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding PocketMichael Forster, Apirat Chaikuad, Silke M Bauer, et al.
Inflammation|January 6, 2026
Inhibition of the JAK/STAT Signaling Pathway Suggests a Protective Effect against Acantholysis in PemphigusFarzan Solimani, Julia Holstein, Katharina Meier, et al.
Scientific Reports|March 15, 2017
Nutritional control of IL-23/Th17-mediated autoimmune disease through HO-1/STAT3 activationJürgen Brück, Julia Holstein, Ivana Glocova, et al.
The Journal of Allergy and Clinical Immunology|November 22, 2020
Immunophenotyping in pemphigus reveals a T<sub>H</sub>17/T<sub>FH</sub>17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody productionJulia Holstein, Farzan Solimani, Carolin Baum, et al.
Theranostics|July 9, 2019
Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactionsJohannes Schwenck, Andreas Maurer, Birgit Fehrenbacher, et al.
Pageof 2